Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Xe129 Magnetic Resonance Imaging of the Lung: A New Technology to Assess Treatment for COPD
Verified date | November 2020 |
Source | University of Virginia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
First, the investigators will image patients with hyperpolarized xenon (Xe) magnetic resonance imaging (MRI) to develop the technique of hyperpolarized xenon MRI at the University of Virginia (UVA). Magnetic Resonance (MR) sequences will need to be developed and optimized for the equipment at UVA. These sequences will need to be evaluated in healthy adults for comparison with results obtained and in adults with lung diseases to optimize the sequences for the detection and evaluation of lung diseases. The MR pulse sequences need to be optimized for the parameters of a human MR coil and the gas exchange characteristics in healthy and diseased lungs. Second, the investigators propose to exploit the power of Xe129 MRI as a diagnostic tool to monitor therapeutic responses of a combination inhaler, Advair, which contains a long-acting beta-adrenoceptor agonist (LABA) and an inhaled corticosteroid (ICS) - two major classes of the current COPD therapeutics. The investigators will characterize the functional changes of the lungs with COPD at baseline, and investigate the responses of the lungs to the treatment after a three-month trial. Also the investigators will compare corresponding results obtained by Xe129 dissolved phase (DP) MRI to the results obtained by gadolinium-based dynamic contrast-enhanced perfusion MRI (perfusion MRI) and high resolution computed tomography (HRCT) of the lung to indirectly validate the Xe129 DP MRI technique. The investigators anticipate that the results from this project will greatly improve the investigators understanding of the lung functional responses of COPD subjects to current therapeutics. Also, the investigators expect that this project will provide evidence to consider Xe129 MRI as a diagnostic strategy to assess and monitor therapeutic responses of existing and new pharmaceuticals, and thus Xe129 MRI will stimulate development of novel therapies for COPD in the future
Status | Completed |
Enrollment | 30 |
Est. completion date | June 15, 2018 |
Est. primary completion date | June 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Subjects should be at their clinical baseline on the day of imaging - Subjects must be clinically stable in order to participate in the study - Smoking history >10 pack years - Subjects must not be currently taking Advair or have taken it within 4 weeks prior to screening - No subject will be withdrawn from Advair to participate in this study The subjects with COPD will be categorized according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD severity classification: - Class 1: forced expiratory volume at one second (FEV1)/forced vital capacity (FVC) < 70 and FEV1 > 80% predicted; - Class 2: FEV1/FVC < 70 and 50% < FEV1 < 80% predicted; - Class 3: FEV1/FVC < 70 and 30% < FEV1 < 50% predicted; - Class 4: FEV1/FVC < 70 and FEV1 < 30% predicted Exclusion Criteria: - Continuous oxygen use at home - Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging - FEV1 percent predicted less than 25% - Pregnancy or lactation - Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning - Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. - Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches. - History of congenital cardiac disease, chronic renal failure, or cirrhosis. - Inability to understand simple instructions or to hold still for approximately 10 seconds. - History of respiratory infection within 2 weeks prior to the MR scan - History of myocardial infarction (MI) , stroke and/or poorly controlled hypertension. - Known hypersensitivity to albuterol or any of its components, or levalbuterol - Glomerular filtration rate (GFR) < 60 ml/min/1.73 m2 or known hypersensitivity to Gd-contrast agents based on a serum creatinine drawn within 30 days of the MRI - Acute kidney injury - History of paraproteinemia syndromes such as multiple myeloma - Hepatorenal syndrome - Liver transplant |
Country | Name | City | State |
---|---|---|---|
United States | University of Virginia | Charlottesville | Virginia |
Lead Sponsor | Collaborator |
---|---|
University of Virginia | National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement in pulmonary airflow physiology detected by Xenon129 MRI | MRI will determine anticipated improvement in patients' airflow limitation correlation ventilation defect. | From baseline to 3 month post treatment with Advair | |
Primary | Improvement in pulmonary gas exchange physiology detected by Xenon129 MRI | Dissolved phase Xe129 of the MRI will determine anticipated improvement in patients' gas exchange capacity in lung tissues correlating with tissue damage caused by COPD. | From baseline to 3 month post treatment with Advair | |
Secondary | Improvement in clinical pulmonary function test | Pulmonary function test will measure anticipated improvement in patients lung function after using Advair. | From baseline to 3 month post treatment with Advair | |
Secondary | St. George's Respiratory Questionnaire | St. George's Respiratory Questionnaire will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair | |
Secondary | Baseline Dyspnea Index | Baseline Dyspnea Index will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair | |
Secondary | Transition Dyspnea Index | Transition Dyspnea Index will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair | |
Secondary | Chronic Respiratory Questionnaire | Chronic Respiratory Questionnaire will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair | |
Secondary | BODE score | BODE score will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair | |
Secondary | GOLD Stage | GOLD Stage will measure anticipated improvement in subjective symptoms of patients. | From baseline to 3 month post treatment with Advair |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|